{'fraction_non_alphanumeric': 0.034220532319391636, 'fraction_numerical': 0.0, 'mean_word_length': 6.121621621621622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical significance of a novel reticulocyte‐based erythropoietin resistance index in HD patients: A retrospective study

The erythropoietin resistance index (ERI) is an indicator of erythropoiesis‐stimulating agent (ESA) responsiveness and is typically calculated using Hb. However, Hb does not directly reflect ESA‐induced erythropoiesis because of its long‐term nature. We thus designed a novel ERI calculated with reticulocyte Hb (RetHb), a real‐time index, and investigated its association with mortality in HD patients.